MICRODROPLET BASED SUSTAINED DELIVERY OF NALTREXONE

微滴是一种改善组织相容性的新方法， 通过溶解水不溶性药物来提供其持续释放 制成微球，（0，1u直径）的油相和包囊 一层磷脂。 将使用大鼠模型来测试 基于微滴技术的麻醉剂持续递送 拮抗剂，纳洛酮。 纳洛酮是治疗的首选药物 因为它本质上是一种纯粹的麻醉剂拮抗剂 并且没有镇痛作用。 一系列微滴的形成 含有不同浓度的纳洛酮， 至少三种组织相容性和FDA批准的合成油。 药物 含有纳洛酮的微滴的释放动力学将是 在体外模型中以及通过皮下和肌内 注射到老鼠身上。 提供可接受（零）的制剂 顺序）在3-4周期间的释放动力学 在II期SBIR中进一步开发其潜在适应症 用于治疗海洛因成瘾者

Microdroplets is a novel means of improving tissue compatibility and providing sustained release of a water insoluble drug by dissolving it into microspheres, (O,1u diameter) of an oil phase and encapsulating them with a layer of phospholipid. A rat model will be used to test the microdroplet technology-based sustained delivery of a narcotic antagonist, naltrexone. Naltrexone is the drug of choice for treatment of heroin addiction because it is essentially a pure narcotic antagonist and devoid of analgesic effects. A series of microdroplet formations containing different concentrations of naltrexone will be prepared in a least three tissue-compatible and FDA approved synthetic oils. The drug release kinetics of the naltrexone-containing microdroplets will be tested in a in vitro model as well as by subcutaneous and intramuscular injections into rats. A formulation which provides acceptable (zero order) release kinetics over a period of 3-4 weeks will be identified for further development in a Phase II SBIR for its potential indication for the treatment of heroin addicts.